
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BMX-101
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Onward Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Biomunex and Onward will jointly develop, in a preclinical and early clinical program (BMX-101), a ‘first-in-class’ immunotherapeutic bispecific antibody, in hematological malignancies, developed by bi- and multi-specific antibody platform BiXAb.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 16, 2021
Lead Product(s) : BMX-101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Onward Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
